Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23159
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKyritsis, A. P.en
dc.date.accessioned2015-11-24T19:30:44Z-
dc.date.available2015-11-24T19:30:44Z-
dc.identifier.issn0890-9091-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23159-
dc.rightsDefault Licence-
dc.subjectAntineoplastic Agents/therapeutic useen
dc.subjectBrain Neoplasms/*drug therapy/therapyen
dc.subjectGlioma/*drug therapy/therapyen
dc.subjectHumansen
dc.titleChemotherapy for malignant gliomasen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8217533-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1993-
heal.abstractAn increase in the incidence of malignant gliomas has been noted over the last two decades. Chemotherapy, either adjuvant or at recurrence, has extended the survival of patients with malignant gliomas. Oligodendrogliomas and anaplastic astrocytomas represent the most chemosensitive tumors, while glioblastomas have been relatively resistant to any treatment modality. The most active agents include carmustine, procarbazine, and eflornithine, and combinations such as lomustine, procarbazine and vincristine, or thioguanine, dibromodulcitol, procarbazine, lomustine, fluorouracil and hydroxyurea. Although chemotherapy has demonstrated some efficacy against malignant glioma, new therapeutic strategies are needed for this devastating disease.en
heal.journalNameOncology (Williston Park)en
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons